Getting closer to hemophilia gene therapy for all?
作者信息
Reiss Ulrike M
机构信息
Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
出版信息
Blood Adv. 2025 Jul 22;9(14):3629-3630. doi: 10.1182/bloodadvances.2025016642.
Abstract
摘要
相似文献
1
Getting closer to hemophilia gene therapy for all?
Blood Adv. 2025 Jul 22;9(14):3629-3630. doi: 10.1182/bloodadvances.2025016642.
2
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2.
3
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
J Manag Care Spec Pharm. 2018 Jul;24(7):632-642. doi: 10.18553/jmcp.2018.24.7.632.
4
Interventions for treating acute bleeding episodes in people with acquired hemophilia A.
Cochrane Database Syst Rev. 2014 Aug 28;2014(8):CD010761. doi: 10.1002/14651858.CD010761.pub2.
5
Gene therapy for hemophilia - From basic science to first approvals of "one-and-done" therapies.
Mol Ther. 2025 May 7;33(5):2015-2034. doi: 10.1016/j.ymthe.2025.03.043. Epub 2025 Mar 27.
6
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Cochrane Database Syst Rev. 2017 Sep 25;9(9):CD011441. doi: 10.1002/14651858.CD011441.pub2.
7
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
N Engl J Med. 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644.
8
Human umbilical cord mesenchymal stem cell-based gene therapy for hemophilia B using scAAV-DJ/8-LP1-hFIXco transduction.
Stem Cell Res Ther. 2024 Jul 18;15(1):210. doi: 10.1186/s13287-024-03824-y.
9
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Cochrane Database Syst Rev. 2011 Sep 7(9):CD003429. doi: 10.1002/14651858.CD003429.pub4.
10
[Gene therapy marks the beginning of a potential "clinical cure" for hemophilia B patients].
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):385-388. doi: 10.3760/cma.j.cn121090-20250304-00111.
本文引用的文献
1
Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.
Blood Adv. 2025 Jul 22;9(14):3543-3552. doi: 10.1182/bloodadvances.2024015291.
2
How to democratize cell and gene therapy: A global approach.
Mol Ther. 2025 May 7;33(5):2082-2090. doi: 10.1016/j.ymthe.2025.03.061. Epub 2025 Apr 2.
3
Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review.
Pharmacoecon Open. 2025 Mar;9(2):179-205. doi: 10.1007/s41669-024-00540-4. Epub 2024 Nov 15.
4
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States.
J Comp Eff Res. 2024 Dec;13(12):e240118. doi: 10.57264/cer-2024-0118. Epub 2024 Nov 14.
5
Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies.
Mol Ther Methods Clin Dev. 2024 May 29;32(3):101273. doi: 10.1016/j.omtm.2024.101273. eCollection 2024 Sep 12.
6
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Lancet Haematol. 2024 Apr;11(4):e265-e275. doi: 10.1016/S2352-3026(24)00006-1. Epub 2024 Mar 1.
7
The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study.
Orphanet J Rare Dis. 2022 Apr 4;17(1):155. doi: 10.1186/s13023-022-02256-2.
8
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
Hum Gene Ther. 2022 Apr;33(7-8):432-441. doi: 10.1089/hum.2021.287. Epub 2022 Mar 16.
9
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.
Zotero 插件